IL1RL2 and cancer: Similar IL-1RL2-neutralizing antibodies are being developed [2,3,4]; however, clinical trials are also ongoing in which IL-36 is used as an adjuvant in cancer immunotherapy (ClinicalTrials.gov ID NCT03739931) [5].